German Health Minister Nina Warken Proposes Sweeping Reforms to Close €15 Billion Deficit

German Health Minister Nina Warken presented a sweeping reform package for the statutory health insurance system on Tuesday, April 14, 2026, targeting a projected deficit of 15 billion euros in the coming year and up to 40 billion euros by 2030. The GKV reform draws from a toolbox of 66 proposals developed by an expert commission at the end of March, of which Warken said she intends to implement more than three-quarters. Key measures include higher medication co-payments, the restriction of free spousal co-insurance starting in 2028, and the removal of coverage for homeopathy and skin cancer screenings. The draft law is scheduled to go before the federal cabinet on April 29, 2026, a timeline Chancellor Friedrich Merz announced the day before the presentation.

„We simply cannot spend more money than we take in.” — Nina Warken via tagesschau.de

Germany's statutory health insurance system has faced structural financing pressure for years, with costs rising faster than revenues. The GKV covers the majority of the German population and is financed through income-based contributions from employees and employers. The current reform effort follows the collapse of the previous "Traffic Light" coalition, which had also struggled with healthcare financing gaps. An expert commission presented 66 savings proposals in late March 2026, forming the basis for Warken's package.

GKV Deficit Projections: Projected deficit — coming year (before: 0 euros (current), after: 15 billion euros); Projected deficit — by 2030 (before: 0 euros (current), after: 40 billion euros)

Spousal co-insurance faces major overhaul from 2028 The most politically contentious element of the package is the restriction of non-contributory co-insurance for spouses in the statutory health insurance system, set to take effect in 2028. Under the current system, spouses without their own income can be covered free of charge under their partner's policy. Under the new rules, previously co-insured spouses would be required to pay a contribution equal to 3.5 percent of the primary insured person's income, capped at approximately 203 euros per month. Exceptions are planned for parents of children under seven years of age, parents of children with disabilities who cannot support themselves, caring relatives, and people of retirement age. The SoVD Chairwoman Michaela Engelmeier described the measure as a "quasi-abolition of non-contributory family insurance," warning it would cause social hardship and disproportionately burden lower-income families. She added that the planned exception for parents of children under seven amounts to little more than a cushioning measure.

„The quasi-abolition of non-contributory family insurance is a completely wrong signal.” — Michaela Engelmeier via ZEIT ONLINE

Spouse Co-Insurance: Before and After 2028: Contribution for co-insured spouse (before: Free of charge, after: 3.5% of primary insured's income, max ~203 euros/month); Exceptions (before: All spouses covered free, after: Parents of children under 7, parents of disabled children, caring relatives, retirees)

Medication Co-Payment Changes: Lower co-payment tier (before: 5 euros, after: 7.50 euros); Upper co-payment tier (before: 10 euros, after: 15 euros)

Coalition partner SPD and Greens push back on insured burden The reform has drawn sharp criticism from across the political spectrum, including from the SPD, the junior partner in Chancellor Merz's black-red coalition. SPD Deputy Parliamentary Group Leader Dagmar Schmidt and health expert Christos Pantazis stated that stabilization of the GKV must not come at the expense of the insured — neither through rising contributions, additional burdens, nor cuts to services. Green Party health expert Janosch Dahmen accused Warken of avoiding the "major cost drivers and influential lobby interests," arguing the reform treats symptoms rather than the structural financing problem of the health insurance funds and represents "a squandered reform opportunity." The German Hospital Association called the cutting plans excessive, unrealistic, and "highly dangerous" for healthcare provision, with association head Gerald Gaß warning the proposals amount to a "state-induced clinic die-off." The German Dermatological Society warned against ending coverage for skin cancer screenings, noting that early detection makes treatment more cost-effective and that late diagnoses drive up therapeutic costs. Eugen Brysch of the German Foundation for Patient Protection complained that the federal government itself was not contributing to closing the financial gap, and that the quality of patient care "continues to play no role."

„Instead of tackling the structural financing problem of the health insurance funds and even providing relief to contribution payers in times of crisis, the symptoms continue to be treated. This is a squandered reform opportunity.” — Janosch Dahmen via Bayerischer Rundfunk

Health insurers split: some back package, others call it unbalanced Reactions from within the health insurance sector were divided. Oliver Blatt, Chairman of the Board of the GKV-Spitzenverband, expressed support, calling the package "a very balanced overall package." Jens Baas, CEO of Techniker Krankenkasse, argued that with a determined cost-containment policy, no benefits would need to be cut, and urged that the expenditure side be fully exhausted before additional burdens are placed on the insured. Carola Reimann, head of the AOK Federal Association, called it unbalanced that more than one-third of the targeted savings are expected to come from contribution payers. The pharmaceutical industry also pushed back: Association President Han Steutel warned that higher mandatory manufacturer discounts on medications would place a heavy burden on companies. The Greens, by contrast, argued the manufacturer discounts could be set even higher, with co-parliamentary group leader Katharina Dröge stating that pharmaceutical corporations should make a larger contribution rather than pressure being repeatedly placed on the insured.

„The manufacturer discounts could be higher. This would mean that pharmaceutical corporations would make a larger contribution, and from our point of view, that would be much fairer than repeatedly trying to exert pressure on the insured.” — Katharina Dröge via tagesschau.de

15 (billion euros) — GKV projected deficit in the coming year

40 (billion euros) — GKV projected deficit by 2030

Coming year: 15, By 2030: 40